Phase I trial of the targeted alpha-particle nano-generator actinium-225 (ac-225)-lintuzumab (anti-CD33; HuM195) in acute myeloid leukemia (AML)

Autor:	Jurcic, J. G., Rosenblat, T. L., Mcdevitt, M. R., Pandit-Taskar, N., Carrasquillo, J. A., Chanel, S. M., Zikaras, K., Frattini, M. G., Peter Maslak, Cicic, D., Larson, S. M., Scheinberg, D. A.
Zdroj:	Memorial Sloan Kettering Cancer Center
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::95a527b1c1900838fb26c10631f3b77a https://synapse.mskcc.org/synapse/works/39995 Zobrazit plný text záznamu